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Main text: 28 
Drug-induced hypersensitivity syndrome (DIHS) ─also termed as drug reaction with 29 
eosinophilia and systemic symptoms (DRESS)─ is a potentially lethal inflammatory disease 30 
associated with human herpesvirus (HHV) reactivation. DIHS/DRESS is classified within a 31 
group of syndromes named severe cutaneous adverse reactions (SCARs), including acute 32 
generalized exanthematous pustulosis and Stevens-Johnson syndrome/toxic epidermal 33 
necrolysis. SCARs are delayed type IV hypersensitivity reactions mainly characterized by T-34 
cell activation. The pathophysiology of DRESS is still poorly understood.1 The proposed 35 
mechanisms implicated in its patogenesis include drug detoxification enzyme abnormalities, 36 
sequential reactivation of herpesviruses (cytomegalovirus, Epstein-Barr virus, HHV-6 and -7), 37 
and genetic predisposition related to certain human leukocyte antigen alleles. The limited 38 
knowledge of the mechanisms and pathways underlying the pathology of DRESS present an 39 
important treatment hurdle.  40 
Over the last few years, targeting specific immunological pathways has become a promising 41 
approach to treat complex inflammatory diseases. In that regard, single-cell RNA sequencing 42 
(scRNA-seq) provides individual cell information at unprecedented resolution. This enables the 43 
analysis of cell lineage trajectories, cell-cell and cell-microenvironment interactions as well as 44 
the identification and discovery of new cell types or phenotypes, which all inform about 45 
pathogenic mechanisms.2,3 For example, He et al. conducted a novel study using scRNA-seq 46 
analysis in atopic dermatitis (AD) and showed a novel fibroblast population directing type 2 47 
immune responses in lesional skin of AD patients.4 48 
Kim et al.5 have recently reported an in-depth study of a DIHS/DRESS patient who was treated 49 
succesfully with the guidance of scRNA-seq. A 44-year-old patient presented with 50 
trimethoprim/sulfamethoxazole-induced DIHS/DRESS. In addition, the patient had generalized 51 
exfoliative dermatitis and uncontrolled systemic symptoms despite prednisone, etanercept, 52 
intravenous immunoglobulin, cyclosporine, and mycophenolate mofetil treatment. The analysis 53 
of skin-derived cells of this patient, in comparison with those of healthy controls (HCs), 54 
revealed an inflammatory state with relative abundance of keratinocytes and immune cells. 55 
Lymphocytes exhibited the greatest transcriptomic changes with T cell predominance and 56 
upregulation of genes involved in proliferation (MKI67), migration (CCR10), activation 57 
(IL2RG) and signaling pathways (JAK3 and STAT1).  58 
The scRNA-seq analysis of peripheral blood mononuclear cells (PBMCs) showed a 59 
predominance of CD4+ and CD8+ subclusters and CCR4- and CCR10-expressing T cells. 60 
Moreover, central memory CD4+ T cells were enriched with DNA from HHV6b. In contrast to 61 
the observation in the skin, JAK and STAT genes were not detected in an unsupervised manner 62 
when the whole PBMC lymphocyte cluster was compared between DiHS/DRESS and HCs. 63 
This shows that the local site of inflammation (skin) was optimal for detecting targetable 64 
pathways. Altogether, these results led to the identification of potential therapeutic targets for 65 
treating this DIHS/DRESS patient, namely the JAK-STAT pathway and the viral infection. The 66 
patient achieved disease control after 2 weeks of treatment with tofacitinib (a JAK1 and JAK3 67 
inhibitor) plus valgancyclovir (an antiviral).   68 
These findings indicate that single-cell omic-based approaches as scRNA-seq might be a 69 
powerful means for directing patient care in diseases with a complex inflammatory 70 
pathophysiology as SCARs. Drug allergy apart, scRNA-seq has been also applied in allergic 71 
asthma. For example, Tibbit et al. showed distinct T helper cell subsets in a mouse model of 72 
house dust mite-induced asthma (REF). In another study, conducted by Vieira Braga et al. in 73 
asthmatic patients and HCs, novel subsets were identified of tissue-resident memory T cells and 74 
mucus ciliated cells (REF).  75 
Although scRNA-seq has been progressively optimized (reduction of costs and number of cells 76 
required for analysis),2,3 there are still difficulties that preclude its implementation in the clinical 77 
practice such as the need for tissue sampling (REF-soumelis) and the complexity of data 78 
analysis and interpretation (REF- by Rostom). The increasing use of techniques such as scRNA-79 
seq, or alike, will likely enlighten the understaning of the pathophysiology of 80 
allergic/immunological diseases, thus enabling the development of targeted therapies.   81 
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Figure 1: scRNA-seq analysis guided successful therapeutic intervention in a patient with 87 
refractory DIHS/ DRESS. A 44 year-old male patient with TMP/SMX-induced DIHS/DRESS 88 
and progression to TEN-like rash and subsequent generalized exfoliative dermatitis and 89 
uncontrolled systemic symptoms was evaluated to find a potential therapeutic target.  Five age- 90 
and sex- matched healthy volunteers were enrolled as a control. Both skin biopsy specimens 91 
and PBMCs were used for scRNA-seq analysis. Four immunological pathways were revealed 92 
at the end of a complex set of analysis: cell proliferation, JAK-STAT pathway, chemokine 93 
receptors and HHV6b proliferation in T lymphocytes with central memory type. Targeting 94 
JAK-STAT pathway with tofacitinib and HHV6b proliferation with valgancyclovir achieved 95 
disease control after 2 weeks of treatment. Pre- and post- treatment scRNA seq analysis of 96 
PBMCs revelaed a reduction of CCR4- and CCR10-expressing CD4+ and CD8+T cells with 97 
proliferative gene signatures consistent with flow cytometry analysis. 98 
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